NCT05542056 Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia
| NCT ID | NCT05542056 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Thiazide-induced Hyponatremia (TIH) |
| Study Type | OBSERVATIONAL |
| Enrollment | 232 participants |
| Start Date | 2022-09-26 |
| Primary Completion | 2026-07 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Thiazides and thiazide-like diuretics are one of the five major classes of antihypertensive drugs. This study is to investigate whether urinary PGE2 concentration at baseline (prior to thiazide initiation) is associated with the development of TIH within the first four weeks of treatment.
Eligibility Criteria
Inclusion Criteria: * Newly prescribed thiazide or thiazide-like diuretic * ≥ 18 years of age * Informed Consent as documented by signature Exclusion Criteria: * Intake of thiazide or thiazide-like diuretic in the preceding month * Hyponatremia (plasma sodium \<135 mmol/L) at baseline * Acute infectious / inflammatory disease (CRP ≥ 20 mg/L \[1, 11\]) * Symptomatic urinary tract infection * Chronic treatment with NSAID and / or NSAID intake 48 hours prior to urine sampling at visit 1 and 2 (intake of acetylsalicylic acid will be no exclusion criteria) * End of life care, no informed consent or inability to follow the procedures of the study, e.g., due to language barriers, psychological disorders, dementia